Mark Davis (@_TSDiaries) header
Mark Davis (@_TSDiaries) profile picture

As a senior stock analyst, my goal is to help investors navigate volatility with confidence and discipline.

Joined July 2011
Photo by Mark Davis (@_TSDiaries)Photo by Mark Davis (@_TSDiaries)Photo by Mark Davis (@_TSDiaries)Photo by Mark Davis (@_TSDiaries)Photo by Mark Davis (@_TSDiaries)Photo by Mark Davis (@_TSDiaries)Photo by Mark Davis (@_TSDiaries)Photo by Mark Davis (@_TSDiaries)Photo by Mark Davis (@_TSDiaries)Photo by Mark Davis (@_TSDiaries)
$VKTX my opinion on GLP-1’s… This is the best drug created since Antibiotics. Abbott is one of the best returns ever in the stock market. They sold erythromycin, a successful antibiotic. What did Antibiotics do? They increased life expectancy of humans by decades. GLP-1’s is the Antibotics of our time. We will see life expectancy rise into the 110-120’s with the benefits of the drug. Before Antibiotics, life expectancy was 47 yrs old. After, into the 70’s. Hold this name for years and years. If it enters the market and is selling, put some orders in for 500$/share within the next 5-10 years
88
$IREN After $NVDA earnings, I'm even more bullish on $IREN What really caught my attention was NVIDIA's discussion around agentic AI and just how massive this could become. Now look at IREN's moves, especially Mirantis. To me, they're hinting at ambitions well beyond GPU rentals. Their own cloud platform, managed services, potentially a token factory, agentic AI infrastructure and multiple recurring revenue streams. And let's not overlook the land and power IREN has already secured. NVIDIA made it clear how critical these are becoming as AI infrastructure expands. Financing and execution remain the challenges, and some of this is my own speculation. But connect the dots... land, power, GPUs, cloud, Mirantis and agentic AI. The pieces are coming together.
1
127
$GRRR 🚀 Short sellers are under serious pressure! Borrow fees have surged to 169.88%, with only 15K shares available to borrow. Rising short costs could set the stage for a potential short squeeze if buying momentum picks up!
9
811
$DVLT 🚀 Strong potential in AI infrastructure and data tokenization. The $200M revenue target is ambitious, but execution and restoring Nasdaq listing are key. Big opportunity, but risks remain!
1
223
$CAPR 🚀 Massive manufacturing expansion ahead! Current capacity could reach 2,500 patients annually, with a new 171K sq ft facility planned for further growth. Big long-term potential beyond DMD!
1
5
477
$ALT Evercore is one of the most prestigious independent investment banks in healthcare M&A, particularly when it comes to negotiating complex transactions between biotech companies and large pharmaceutical companies.
2
156
To summarize the last 10 days of $CRWV • They crushed earnings - Revenue: $3.66B (Est. $3.55B); +168% YoY • $NVDA interim CEO Colette Kress says neoclouds are seeing “extraordinary demand” but growing faster than their balance sheets can support so Nvidia is helping secure land, power and data center capacity • Chief Strategy Officer purchased $30 Million worth of bonds • $ANT IPO day - Anthropic’s first priority for its IPO cash will be buying more computing power to reach recursive self-improvement before its rivals. — NYT (they have a deal with CoreWeave)
58
ZenaTech, Inc. (NASDAQ: $ZENA) has announced the launch of a new entertainment division, ZenaStudios, dedicated to producing original films, streaming content, and digital media products. The division will develop and own original intellectual property (IP), while leveraging ZenaTech’s proprietary autonomous drone technology—utilizing it both as a narrative element on-screen and as a production tool behind the scenes. ZenaTech, Inc. is one of the key companies represented by B2i Digital. On November 9, ZenaStudios debuted its first series, an 11-episode production titled *The Money System: Crossing the Street*, on its official YouTube channel. • In the series, as a jury deliberates, the only impartial witness—an autonomous drone that captured the crime—effectively serves as a "13th juror" in the trial. • The series stars actor and creator Mae Belen, with additional cast members including Tanya Jade, Kye Cartwright, and Gavin Etmanski. • The narrative of *The Money System: Crossing the Street* leads directly into a standalone feature film, *The Money System: Weight of Evidence*, which is currently in pre-production. ZenaTech has appointed Bobby Kelly as Head of Development for the ZenaStudios office in Los Angeles. Commenting on this new division, Dr. Shaun Passley, CEO of ZenaTech, stated: "This division will not only enhance our brand visibility but also create new opportunities for our drone services, product placements, and commercial partnerships."
56
$CBRS 10 funds 53% and increasing
1
223
$GRRR $GRRR Short sellers are getting absolutely hammered with borrow fees! Fintel now showing 132.34% annualized, up from 109.10% yesterday and nearly double the 68.75% starting rate on Nov 5. Meanwhile, reported short interest has climbed to 6.64 MILLION shares, up 11.23% from the previous report, with 5.45 days to cover. Depending on the float calculation, that’s roughly 26–52% short interest! At these borrow rates, maintaining a $1M short position costs approximately $3,626 PER DAY. Shorts are paying a massive premium to maintain their positions. With earnings approaching, any significant buying pressure or positive catalyst could create serious covering pressure. The setup is getting increasingly interesting. 🔥🚀
1
13
1,143
A dedicated WhatsApp group for $GRRR holders is now online! All investors holding $GRRR stock are welcome to join this exclusive group to discuss the stock and get the latest information. Click the link to send“stock” join:stockswhatsapp.app/UHXA2p Our assistant Victoria is available to assist you anytime!
65
$VKTX The Road to a Potential 2029 Launch 2027 is expected to bring the first major Phase 3 results for VK2735, plus maintenance data and progress with VK3019. Oral VK2735 Phase 3 results are expected in 2028. Viking targets a potential 2029 launch, subject to approval. 2027 – Decision Year • First major Phase 3 results for VK2735 (H2 2027). • Second maintenance study results (mid-2027). • Further progress with VK3019, Viking's amylin candidate. 2028 – Validation Year • Results from the oral VK2735 Phase 3 trials. • VANQUISH extension study results. • Further data on safety, effectiveness and long-term weight maintenance. 2029 – Commercialization • Potential regulatory submissions and approval. • Targeted market launch of VK2735. • Start of sales and potential revenue. Looking Ahead – My Take The 2027–2029 period could be a turning point for Viking. Positive clinical results and regulatory approval could make the company a major player in the fast-growing obesity-treatment market.
4
342
$NWBO IMO this points to NWBO using the former Charles River Labs - now Rose Biosolutions - as their US manufacturer AND testing Flashworks at their facility in Sommerville. That type of facility could theoretically be suitable for: - Flaskworks engineering. - Eden system testing. - Cell-processing experiments. - Manufacturing workflow development. - Equipment validation and optimization. Nov 2 "CEO David Enloe contends the new standalone Rose BioSolutions fills a gap in the cell and gene therapy market for a truly end-to-end CDMO, providing a full suite of cell therapies... as well as cell supply operations." "Enloe said. 'We’ve got a couple of critical clients that are at the altar with respect to FDA. We’re maturing our systems and preparing for those inspections.' Rose BioSolutions manufactures autologous and allogeneic cell therapies, as well as gene therapies... and provides human immune and stem cells for basic research and (GMP) cellular starting materials.”
2
1
60
1,522
$TTWO According to data from Sensor Tower, as of Thursday morning, global sales of Grand Theft Auto VI had surpassed 17 million units, generating approximately $1.65 billion in cumulative revenue. This remarkable performance highlights the extraordinary demand for Rockstar Games’ highly anticipated blockbuster, setting an impressive benchmark for the gaming industry and reinforcing strong market expectations for Take-Two Interactive’s future growth and profitability.
95
$ALLR strengthens its long-term IP position for stenoparib! Allarity Therapeutics secured a new U.S. patent protecting its clinical dosing regimen through 2045. 📊 Why it matters: > 36 allowed claims covering twice-daily oral dosing. > Covers ovarian cancer and other solid tumors. > Includes treatment-resistant cancers, including those resistant to prior PARP inhibitors. > Protects the dosing strategy planned for future pivotal trials. The patent complements Allarity's existing patent for its proprietary DRP companion diagnostic, strengthening its personalized treatment strategy. 🚀 Stronger IP could support future partnerships and commercialization
4
902
$HTZ this is like almost no shares available.
1
17
682
$EOSE breadcrumbs… On Nov. 5, Eos disclosed 3.5 GWh of late-stage opportunities, more than its entire Q3 backlog, and said it expected more clarity on near-term deals within 4–5 weeks. Management also highlighted California’s push for long-duration storage. Now Southern California Edison has Nov. 18 on the calendar for shortlist notifications in its long-duration storage procurement, with follow-up submissions due Nov. 25. That timing fits, though Eos hasn’t publicly linked any of its 3.5 GWh to this solicitation. SCE could notify bidders privately, so public silence tomorrow would tell us little. Tomorrow 🤙
4
1
42
3,574
A dedicated WhatsApp group for $EOSE holders is now online! All investors holding $EOSE stock are welcome to join this exclusive group to discuss the stock and get the latest information. Click the link to send“stock” join:stockswhatsapp.app/UHXA2p Our assistant Victoria is available to assist you anytime!
113
$NWBO The Company previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer. NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables the Company to produce its personalized vaccine in an efficient, cost-effective manner. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company’s lead product, DCVax-L, is currently in a 348-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. The Company’s second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers. The Company has also conducted a Phase I/II trial with DCVax for late stage ovarian cancer together with the University of Pennsylvania.
1
4
610
🚨 BREAKING: $HIMS LAUNCHES PEPTIDES+ Available now: Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine BPC-157 and TB-500 to be added later Wolverine ^^^ Sermorelin: $149/mo Glutathione: $99/mo NAD+: $149/mo L-carnitine: $129/mo Vitamin B-12: $99/mo Folks that worked their whole lives now get a chance to live well 💪 and pain free
2
1
23
860
$SOFI A strategic plan announced on November 18 outlines SoFi’s goals for 2030: Build five independent business units, each generating at least $1 billion in annual revenue. Reach a total of 100 million platform products. Expand cryptocurrency-related services. Scale up payment operations. Develop an enterprise banking business. Reduce over-reliance on traditional lending. The significance of this strategy: SoFi aims to evolve into a comprehensive financial platform, moving beyond a business model that depends solely on personal, student, and mortgage loans. If successfully executed, this would lead to more diversified revenue streams and potentially shift the company’s valuation—moving it away from that of a traditional consumer finance firm toward that of a fintech platform. However, these 2030 targets represent management’s strategic objectives and have not yet been achieved.
3
5
1
58
2,183